Treatment of mastalgia with tamoxifen in male patients with liver cirrhosis: A randomized crossover study

American Journal of Gastroenterology

Volumn 95, Issue 4, 2000, Pages 1051-1055

  Li, Chung Pin ^a,b   Lee, Fa Yauh ^a,b   Hwang, Shinn Jang ^a,b   Chang, Full Young ^a,b   Lin, Han Chieh ^a,b   Kuo, Benjamin Ing Tiau ^a,b   Chu, Chi Jen ^a,b   Lee, Shou Dong ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; PLACEBO; SPIRONOLACTONE; TAMOXIFEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ESTRADIOL BLOOD LEVEL; HUMAN; LIVER CIRRHOSIS; MALE; MASTALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

AGED; BREAST; CROSS-OVER STUDIES; ESTRADIOL; ESTROGEN ANTAGONISTS; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PAIN; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; SPIRONOLACTONE; TAMOXIFEN; TESTOSTERONE; TREATMENT OUTCOME;

EID: 0034032425     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)00772-3     Document Type: Article

References (20)

1. Chopra I.J., Tulchinsky D., Greenway F.L. Estrogen-androgen imbalance in hepatic cirrhosis Studies in 13 male patients . Ann Intern Med. 79:1973;198-203.
2. Nagasue N., Ogawa Y., Yukaya H., et al. Serum levels of estrogens and testosterone in cirrhotic men with and without hepatocellular carcinoma. Gastroenterology. 88:1985;768-772.
3. Greenblatt D.J., Koch-Weser J. Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program. JAMA. 225:1973;40-43.
4. Gabbrielli G., Binazzi P., Scaricabarozzi I., et al. Nimesulide in the treatment of mastalgia. Drugs. 46:(suppl 1):1993;137-139.
5. BeLieu R.M. Mastodynia. Obstet Gynecol Clin North Am. 21:1994;461-477.
6. Butt J.H., Barthel J.S., Hosokawa M.C., et al. NSAIDs A clinical approach to the problems of gastrointestinal side-effects . Aliment Pharmacol Ther. 2:(suppl 1):1998;121-129.
7. Chen L.S., Lin H.C., Lee F.Y., et al. Prevalence of duodenal ulcer in cirrhotic patients and its relation to Helicobacter pylori and portal hypertension. Chin Med J (Taipei). 56:1995;226-231.
8. Chen L.S., Lin H.C., Hwang S.J., et al. Prevalence of gastric ulcer in cirrhotic patients and its relation to portal hypertension. J Gastroenterol Hepatol. 11:1996;59-64.
9. Gentilini P. Cirrhosis, renal function and NSAIDs. J Hepatol. 19:1993;200-203.
10. Woitas R.P., Heller J., Stoffel-Wagner B., et al. Renal functional reserve and nitric oxide in patients with compensated liver cirrhosis. Hepatology. 26:1997;858-864.
11. Jefferys D.B. Painful gynecomastia treated with tamoxifen. Br Med J. 1:1979;1119-1120.
12. Fentiman I.S., Caleffi M., Hamed H., et al. Dosage and duration of tamoxifen therapy for mastalgia A controlled trial . Br J Surg. 75:1988;845-846.
13. McDermott M.T., Hofeldt F.D., Kidd G.S. Tamoxifen therapy for painful idiopathic gynecomastia. South Med J. 83:1990;1283-1285.
14. Serels S., Melman A. Tamoxifen as treatment for gynecomastia and mastodynia resulting from hormonal deprivation. J Urol. 159:1998;1309.
15. Di Lelio A., Cestari C., Lomazzi A., et al. Cirrhosis Diagnosis with sonographic study of the liver surface . Radiology. 172:1989;389-392.
16. Pugh R.N., Murray-Lyon I.M., Dawson J.L., et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 60:1973;646-649.
17. Parker L.N., Gray D.R., Lai M.K., et al. Treatment of gynecomastia with tamoxifen A double-blind crossover study . Metabolism. 35:1986;705-708.
18. Sherlock S., Dooley J. Endocrine changes in hepatocellular failure. Sherlock S., Dooley J. Diseases of the liver and biliary system. 1993;73-85 Blackwell Scientific Publications, Oxford.
19. Adam H.K., Douglas E.J., Kemp J.V. The metabolism of tamoxifen in human. Biochem Pharmacol. 28:1979;145-147.
20. Riestra S., Rodriguez M., Delgado M., et al. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J Clin Gastroenterol. 26:1998;200-203.